GPRC5D×CD3 bispecific T-cell–redirecting antibody that engages T cells to kill myeloma cells expressing GPRC5D.
Humanized bispecific antibody that binds CD3 on T cells and GPRC5D on myeloma cells, cross-linking them to activate cytotoxic T cells and induce perforin/granzyme-mediated lysis of GPRC5D-expressing tumor cells.
Talquetamab bridges CD3 on T cells to GPRC5D on target cells, activating T cells to kill GPRC5D-expressing cells via perforin/granzyme-mediated cytolysis.
Anti-CD38 monoclonal antibody mediating ADCC, CDC, and phagocytosis against myeloma cells.
Human IgG1 kappa anti-CD38 monoclonal antibody that binds CD38 on myeloma and other CD38+ cells, inducing Fc-mediated antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), complement-dependent cytotoxicity (CDC), and direct apoptosis; depletes CD38+ tumor cells and CD38-expressing immunosuppressive cells, enhancing antitumor immunity.
Anti-CD38 IgG1 binds CD38 on target cells and triggers NK cell–mediated ADCC, macrophage ADCP, complement-dependent cytotoxicity (CDC), and can induce direct apoptosis.
BCMA×CD3 bispecific T-cell–redirecting antibody that brings T cells into proximity with BCMA-positive myeloma cells.
Bispecific antibody that binds CD3 on T cells and BCMA (TNFRSF17) on myeloma cells, bringing T cells into close proximity to BCMA-positive plasma cells to form an immune synapse and trigger CTL activation and perforin/granzyme-mediated lysis of the tumor cells.
Teclistamab links CD3+ T cells to BCMA+ cells, triggering CTL activation and immune-synapse–mediated perforin/granzyme cytolysis of the BCMA-expressing cells.
Also known as PRO1107, a PTK7-targeted monoclonal antibody–drug conjugate (ADC) that binds PTK7 on tumor cells, is internalized, and releases a cytotoxic payload to induce tumor cell death.
PTK7-targeted monoclonal antibody-drug conjugate that binds PTK7 on tumor cells, is internalized, and releases an intracellular cytotoxic payload via linker cleavage, leading to tumor cell death.
An anti-PTK7 antibody-drug conjugate binds PTK7 on the cell, is internalized, and upon linker cleavage releases an intracellular cytotoxic payload that kills the PTK7-expressing cell.
Anti‑HER2 monoclonal antibody that inhibits HER2 signaling and mediates antibody‑dependent cellular cytotoxicity (ADCC).
Humanized IgG1 monoclonal antibody that binds HER2 (ERBB2), blocks receptor dimerization and downstream signaling (e.g., PI3K/AKT, MAPK), promotes receptor internalization/degradation, and engages immune effector cells via Fc to mediate ADCC against HER2‑overexpressing tumor cells.
Fc-mediated ADCC via FcγR-expressing immune cells (e.g., NK cells) against HER2+ cells; may also contribute via CDC and apoptosis from HER2 signaling blockade.